

Date: 12.08.2022

To
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Subject: Press Release- corrigendum

Dear Sir/ Madam,

Further to our letter dated, 10.08.2022, Corrigendum is being issued to inform the stakeholders of the Company regarding amendment in Q2FY23 column of updates on CAPEX in the press release issued on August 10, 2022.

Request you to please take of note of the same.

Thanking You

Yours Faithfully,

For Natural Capsules Limited



Shilpa Burman
Company Secretary & Compliance Officer



NATURAL CAPSULES LIMITED REPORTS Q1FY23 RESULTS

Bangalore, August 10th, 2022: Natural Capsules Limited, one of India's leading manufacturer of hard capsules shell has announced its financial results for the first quarter ended June 30th, 2022.

FINANCIAL HIGHLIGHTS FOR QUARTER ENDED JUNE 30th, 2022

REVENUES		EBITDA		EBITDA MARGINS	
↑ 6.36%	↑ 71.90%	↑ 12.37%	↑ 114.82%	↑ 110 BPS	↑ 414 BPS
PAT		EPS		Key	
↑ 2.65%	↑ 144.15%	↑ 6.81%	↑ 117.02%	↑ Q-o-Q	↑ Y-o-Y

COMMENTING ON THE PERFORMANCE, MR. SUNIL MUNDRA, EXECUTIVE DIRECTOR, SAID,

"I am pleased to provide you with an update on our performance during the quarter. We have had a strong start to FY23, continuing our growth momentum from last year. The increase in topline was driven by a combination of higher realisation and higher volumes. However, the new line added became operational only in June, moderating our volumetric growth for the quarter. In addition, we witnessed a slow intake of new orders in domestic markets for our capsule business; however, traction in export markets remained strong. Domestic demand has rebounded in the second quarter, and we expect the strong momentum to continue through the year. With the ramp-up of the newly commissioned line and incremental capacity scheduled in Q2, we anticipate strong volumetric growth in the second half of the fiscal year. Furthermore, as we continue to add newer generation machines, we remain optimistic about further enhancing our profitability margins.

We remain on track with our CAPEX plans in the API business and expect to begin commercial production in Q1FY24. As previously reported, due to cost overruns, we have increased our CAPEX guidance for the API business from ₹ 98 crores to ₹ 115 crores. This will undoubtedly affect our expected asset turns on the project. However, I am pleased to report that we already have Letters of Intent in place from buyers in the United States, Japan, and the domestic market for more than ₹ 100 crores on an annualised basis. With this, we remain confident of exceeding 50% capacity utilisation in the first year of operation, enabling us to cash breakeven.

A favourable demand environment and increasing operational capacity give us the confidence that we will be able to build on our current position and deliver strong financial results in the times to come."

UPDATES ON CAPEX

	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23
CAPSULES	<ul style="list-style-type: none"> Added 1 line for gelatin capsules in Bengaluru plant 	<ul style="list-style-type: none"> Added 1 line for gelatin capsules in Bengaluru plant in June 	<ul style="list-style-type: none"> 1 line for gelatin capsules to be added in August 	<ul style="list-style-type: none"> 2 lines for HPMC capsules to be added in Q3FY23 	<ul style="list-style-type: none"> 1 line for HPMC capsules to be added in Q4FY23
API			<ul style="list-style-type: none"> Expected installation of machines and equipment in the fermentation and synthesis blocks 		<ul style="list-style-type: none"> Plans to commence equipment validation batches and dry trial runs. Commercial production to begin from Q1FY24

ABOUT NATURAL CAPSULE LIMITED (NCL)

Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limited Company in 1993 at Bangalore, and it further expanded its operations to Pondicherry in 2003. The company is now foraying into API manufacturing with complex high-end patented technology developed in-house, under its wholly owned subsidiary company Natural Biogenex Private Limited.

For further details please get in touch with

Shilpa Burman
NATURAL CAPSULE LIMITED
Email: company.sec@naturalcapsules.com

Abhishek Mehra
TIL ADVISORS PRIVATE LIMITED
Email: abhishek@theinvestmentlab.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Natural Capsules Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.